Moderna shares rise 5.97% after-hours after raising 2025 revenue forecast to $1.9B and outlining expense cuts.

Moderna

Moderna Inc's GF Score Indicates Potential Challenges Ahead: Financial Strength, Growth, and Valuation Rankings Suggest Underperformance

Moderna shares rise 5.82% intraday after exceeding 2025 revenue forecast and cutting operating expenses.

Arbutus Biopharma

Arbutus Biopharma shares fall 14% after European Patent Office revokes patent in dispute with Moderna.

Intuitive Surgical

Exxon Mobil

Wednesday's Notable Options Activity: ISRG, XOM, and MRNA

Catalyst<ul> <li>RSI Overbought signal on 20260114 indicates strong bullish momentum for MRNA.</li> <li>Fund flow analysis shows positive net inflow trends across small, medium, and large order sizes.</li></ul>Risk<ul> <li>Technical indicators show bearish signals are obviously dominant with 3 bearish versus 1 bullish in recent periods.</li> <li>The overall technical trend is weak with a recommendation to avoid MRNA due to unclear directional movement.</li> <li>Analyst ratings for MRNA are mixed with only a Neutral rating from one active analyst, indicating a lack of consensus and pessimistic market expectations.</li></ul>

Key Factors

Moderna (MRNA) raised its 2025 revenue forecast to $1.9 billion and announced $200 million in operating expense cuts in early 2026. Moderna shares surged over 5.8% intraday after preliminary 2025 revenues exceeded guidance and operating expenses were reduced. A European Patent Office decision to revoke Arbutus Biopharma’s EP 2279254 patent indirectly impacts Moderna, as the patent was central to a legal dispute between Arbutus and MRNA.

Recent Updates

MRNA News